Risankizumab for narrowed bowel in Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether risankizumab can help people with a type of Crohn's disease where the intestine becomes narrowed (fibrostenotic) and causes symptoms like cramping or vomiting. The goal is to see if the drug can reduce inflammation and improve these blockages.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a confirmed diagnosis of fibrostenotic Crohn's disease, meaning a narrowed intestine from scar tissue.
- You must have symptoms like cramping, vomiting after meals, or abdominal pain linked to the narrowing.
- The narrowing must be new (not treated with dilation or stenting in the past year), less than 10 cm long, and no more than 2 in one section.
- You must have already tried standard treatments like azathioprine or other biologics without success, or you can't take them.
- You cannot have used risankizumab or ustekinumab before; other biologics need a washout period (e.g., at least 8 weeks for TNF inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ustekinumab, a medicine that calms immune inflammation, to see if it can improve symptoms in people with Crohn’s disease that causes bowel narrowing. It may help if your Crohn’s symptoms come from strictures (narrowed areas) seen on scans or endoscopy.
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
This trial tests a drug called risankizumab (Skyrizi) for people whose Crohn's disease has led to anal fistulas that haven't improved with other treatments. The goal is to see if risankizumab can help these fistulas heal and stop draining.
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
This trial tests a new imaging method using a special dye (risankizumab-800CW) to see how risankizumab, a medicine for inflammatory bowel disease, works in the bowel. The goal is to better understand the medicine's effects and help doctors tailor treatments.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.